Finally, our results showing that systemic HK2 deletion after tumor onset, which emulates drug therapy, inhibited breast cancer metastasis provided a proof of concept for targeting HK2 to inhibit breast cancer metastasis. The gene discussed is HK2; the disease is neoplasm.